Abbott Shares Tumble 1.47% as Earnings Pressures and FDA Delays Push Trading Volume to 282nd in Market Activity

Abbott (ABT) closed at a 1.47% decline on Sept. 24, with a trading volume of $0.37 billion—47.28% lower than the previous day’s figure—ranking it 282nd in market activity. The drop followed a mixed earnings report highlighting margin pressures despite revenue growth in its diagnostics segment. Analysts noted the stock’s sensitivity to macroeconomic uncertainties, particularly in emerging markets where Abbott’s diabetes care business remains exposed to currency volatility.

Recent regulatory developments in the U.S. also impacted sentiment. The FDA’s revised guidance on over-the-counter medical device approvals delayed Abbott’s pipeline expansion plans by 6-8 weeks, according to internal communications leaked to industry publications. While the company reaffirmed its long-term growth targets, short-term operational risks have heightened, prompting several brokerages to downgrade their price targets for the stock.

Back-test parameters for evaluating volume-based trading strategies require clarification on implementation details: stock universe scope, entry/exit timing, weighting methodology, transaction cost assumptions, and risk controls. Confirmation of these elements will enable accurate signal generation and performance analysis from Jan. 1, 2022, through the latest available close on Sept. 24, 2025.